{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:41:34Z","timestamp":1792003294885,"version":"4.4.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.ygyno.2015.07.018","type":"journal-article","created":{"date-parts":[[2015,7,16]],"date-time":"2015-07-16T00:51:15Z","timestamp":1437007875000},"page":"507-512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology\/Gynecologic Oncology Group study"],"prefix":"10.1016","volume":"138","clinical-trial-number":[{"clinical-trial-number":"nct00977574","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"David","family":"Bender","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Sill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Lankes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry D.","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Darus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Delmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Rotmensch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi J.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Mannel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne M.","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark I.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn K.","family":"McCourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan I.","family":"Samuelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly K.","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2015.07.018_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2015.07.018_bb0010","series-title":"Cancer Facts and Figures","year":"2011"},{"key":"10.1016\/j.ygyno.2015.07.018_bb0015","series-title":"SEER Cancer Statistics Review","first-page":"1975","author":"Howlader","year":"2013"},{"key":"10.1016\/j.ygyno.2015.07.018_bb0020","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.ygyno.2012.03.034","article-title":"Abstract: randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study","volume":"125","author":"Miller","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.07.018_bb0025","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2010.32.6397","article-title":"Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study","volume":"29","author":"Aghajanian","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.07.018_bb0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ygyno.2012.12.022","article-title":"Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study","volume":"129","author":"Alvarez","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.07.018_bb0035","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1200\/JCO.2006.07.2066","article-title":"Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors","volume":"25","author":"Drevs","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.07.018_bb0040","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ccr.2006.11.021","article-title":"AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients","volume":"11","author":"Batchelor","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2015.07.018_bb0045","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1200\/JCO.2009.23.2777","article-title":"Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer","volume":"27","author":"Matulonis","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.07.018_bb0050","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/bjc.2011.334","article-title":"Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer","volume":"105","author":"Raja","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2015.07.018_bb0055","series-title":"Presented at the 2013 NCRI Cancer Conference","article-title":"Abstract: randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial","author":"Ledermann","year":"2013"},{"key":"10.1016\/j.ygyno.2015.07.018_bb0060","series-title":"Presented at the ESMO 2014 Congress","article-title":"CIRCCa: a randomised double blind phase II trial of carboplatin\u2013paclitaxel plus cediranib versus carboplatin\u2013paclitaxel plus placebo in metastatic\/recurrent cervical cancer","author":"Symonds","year":"2014"},{"key":"10.1016\/j.ygyno.2015.07.018_bb0065","series-title":"Atlas of Stains: A Better Path for Cancer Diagnostics","year":"2012"},{"key":"10.1016\/j.ygyno.2015.07.018_bb0070","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.canlet.2012.12.016","article-title":"Microvessel density and p53 mutations in advanced-stage epithelial ovarian cancer","volume":"331","author":"Nadkarni","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ygyno.2015.07.018_bb0075","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1740774512450101","article-title":"A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage phase II clinical trials","volume":"9","author":"Sill","year":"2012","journal-title":"Clin. Trials"},{"key":"10.1016\/j.ygyno.2015.07.018_bb0080","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2307\/1412159","article-title":"The proof and measurement of association between two things","volume":"15","author":"Spearman","year":"1904","journal-title":"Am. J. Psychol."},{"key":"10.1016\/j.ygyno.2015.07.018_bb0085","doi-asserted-by":"crossref","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"10.1016\/j.ygyno.2015.07.018_bb0090","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ygyno.2012.07.127","article-title":"Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer","volume":"127","author":"Leslie","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.07.018_bb0095","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ygyno.2013.02.019","article-title":"A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study","volume":"129","author":"Leslie","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.07.018_bb0100","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ygyno.2012.08.020","article-title":"A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study","volume":"127","author":"Coleman","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.07.018_bb0105","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1200\/JCO.2010.34.1578","article-title":"Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group","volume":"29","author":"Oza","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.07.018_bb0110","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1158\/0008-5472.CAN-04-4409","article-title":"AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer","volume":"65","author":"Wedge","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2015.07.018_bb0115","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1200\/JCO.2007.14.4741","volume":"26","author":"Laurie","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.07.018_bb0120","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1158\/1078-0432.CCR-13-2507","article-title":"Biologic effects of platelet-derived growth factor receptor \u03b1 blockade in uterine cancer","volume":"15","author":"Roh","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.07.018_bb0125","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ctrv.2013.11.004","article-title":"Targeting molecular pathways in endometrial cancer: a focus on the FGFR pathway","volume":"40","author":"Lee","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ygyno.2015.07.018_bb0130","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1158\/1535-7163.MCT-12-1240","article-title":"Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model","volume":"12","author":"Zhang","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2015.07.018_bb0135","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ygyno.2010.08.016","article-title":"Predictive and prognostic angiogenic markers in gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer","volume":"119","author":"Han","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.07.018_bb0140","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ygyno.2008.11.013","article-title":"Markers of angiogenesis in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study","volume":"112","author":"Randall","year":"2009","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815300792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815300792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:36:56Z","timestamp":1717979816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825815300792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0090825815300792"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.07.018","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology\/Gynecologic Oncology Group study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}